Navigation Links
OncoGenex Pharmaceuticals Added to Russell Indexes
Date:6/30/2009

true opportunity set.

Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for both passive and active investment strategies. An industry-leading $4 trillion in assets currently are benchmarked to them. These investment tools originated from Russell's multi-manager investment business in the early 1980s when the company saw the need for a more objective, market-driven set of benchmarks in order to evaluate outside investment managers.

Total returns data for the Russell 3000 and other Russell Indexes is available at http://www.russell.com/Indexes/performance/default.asp.

About OncoGenex

OncoGenex is a biopharmaceutical company committed to the development and commercialization of new therapies that address unmet needs in the treatment of cancer. OncoGenex has a deep oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OGX-011, the lead candidate that has completed five Phase 2 clinical trials in prostate, lung and breast cancers, is designed to inhibit the production of a specific protein associated with treatment resistance; OGX-427 is in Phase 1 clinical development; SN2310 has completed the Phase 1 clinical trial; and CSP-9222 and OGX-225 are currently in pre-clinical development.

OGX-011, OGX-427 and OGX-225 utilize second-generation antisense technology, licensed from Isis Pharmaceuticals (NASDAQ: ISIS), to effectively target and inhibit production of specific proteins in tumor cells. OncoGenex and Isis partnered in the successful discovery of OGX-011, OGX-427 and OGX-225 and with respect to OGX-011, in its initial development. In 2008, OncoGenex and Isis amended their
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. OncoGenex Pharmaceuticals Files Shelf Registration Statement
2. OncoGenex Pharmaceuticals Completes Amendment to Phase 3 Special Protocol Assessment for Confirming Survival Benefit in Patients Receiving OGX-011 with First-Line Docetaxel for Metastatic Prostate Cancer
3. OncoGenex Pharmaceuticals Announces OGX-011 Treatment Provides Survival Benefit in Randomized Phase 2 Trial in Advanced Metastatic Prostate Cancer
4. OncoGenex Pharmaceuticals Announces OGX-427 Treatment Demonstrates Safety, Evidence of Declines in Circulating Tumor Cells and Reductions in Tumor Markers in a Phase 1 Cancer Trial
5. OncoGenex Pharmaceuticals to Webcast ASCO Reception on May 30, 2009
6. OncoGenex Pharmaceuticals Announces Release of Two ASCO Abstracts: Impact of OGX-011 on Survival in Randomized Phase 2 Trial and Phase 1 Safety Data for OGX-427
7. OncoGenex Pharmaceuticals Clinical Programs to be Featured in Oral Presentations at the American Society of Clinical Oncology Annual Meeting
8. OncoGenex Reports First Quarter Financial Results
9. OncoGenex Pharmaceuticals to Release First Quarter Financial Results
10. OncoGenex Receives Confirmation from FDA on the Design of a Second Phase 3 Trial Evaluating OGX-011 for the Treatment of Advanced Prostate Cancer
11. OncoGenex Pharmaceuticals Named Life Sciences Company of the Year by LifeSciences British Columbia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... 2014 SoundConnect , a ... as one of the nation’s Fastest Growing Private ... the 2nd consecutive year. Inc. magazine today ranked ... 500|5000, an exclusive ranking of the nation's fastest-growing ... look at the most important segment of the ...
(Date:8/20/2014)... time, chemists have succeeded in measuring vibrational motion of ... study reveals how vibration of a single molecule differs ... The study was performed at the University of California, ... of Jyvskyl works as a visiting fellow under professor ... The second team was lead by Professor Eric O. ...
(Date:8/20/2014)... Francisco, CA (PRWEB) August 20, 2014 ... Conference is being held on October 29-30 in ... perspectives from industry, academic and government researchers and clinicians ... in the space. , In the twelve years ... one hundred therapies have been introduced with pharmacogenetic information ...
(Date:8/20/2014)... (PRWEB) August 20, 2014 ... released today including improvements to the enterprise replication ... connectors for Lucene, SOLR and Elasticsearch. This release ... this high performance triplestore – GraphDB™ was formerly ... in deploying the only mature enterprise resilient RDF ...
Breaking Biology Technology:SoundConnect Returns on Inc. 5000 List of Fastest Growing Companies 2SoundConnect Returns on Inc. 5000 List of Fastest Growing Companies 3Seeing a molecule breathe 26th Annual Personalized and Precision Medicine Conference Bringing Together Thought Leaders to Discuss Clinical Implementation, Dx Reimbursement, Big Data, and Sequencing 2Ontotext Improves Its RDF Triplestore, GraphDB™ 6.0: Enterprise Resilience, Faster Loading Speeds and Connectors to Full-Text Search Engines Top the List of Enhancements 2Ontotext Improves Its RDF Triplestore, GraphDB™ 6.0: Enterprise Resilience, Faster Loading Speeds and Connectors to Full-Text Search Engines Top the List of Enhancements 3Ontotext Improves Its RDF Triplestore, GraphDB™ 6.0: Enterprise Resilience, Faster Loading Speeds and Connectors to Full-Text Search Engines Top the List of Enhancements 4
... announced Wednesday that it has begun shipping Gen2 RFID-tagged cases ... Auto-ID research lab in Neenah, Wis., to thank for it. ... of Huggies brand diapers is the company's next step in ... extensive research and testing on the compatibility of Gen2 hardware ...
... wearing paper goggles gasped frequently as they watched a human ... from La Crosse to Madison. , , ... of the applications he's developed at UW-La Crosse. It ... the foundation for educational software on anatomy. It was also ...
... not necessarily their best mind you, growing up was "Aftermath", an ... of BIO 2006- Chicago. , ,As BIO 2006 - Chicago is ... take on the outcome, but so many others have already done ... and some more of the facts emerge (like the final attendance ...
Cached Biology Technology:Neenah lab helps firm ship RFID-tagged products to Wal-Mart 2Next generation simulations? Not on the Internet you're used to 2BIO 2006 aftermath and a taste of bio-generics 2BIO 2006 aftermath and a taste of bio-generics 3BIO 2006 aftermath and a taste of bio-generics 4BIO 2006 aftermath and a taste of bio-generics 5BIO 2006 aftermath and a taste of bio-generics 6BIO 2006 aftermath and a taste of bio-generics 7BIO 2006 aftermath and a taste of bio-generics 8
(Date:8/20/2014)... The National Institutes of Health has awarded the Oklahoma ... continue its research on anthrax and the bacteria,s effects ... Mark Coggeshall, Ph.D., and his colleagues have studied the ... NIH,s Cooperative Centers for Human Immunology. The original funding ... 17 on the heels of the terrorist attacks of ...
(Date:8/20/2014)... causes a burning spiciness that is irresistible to some, ... effect are using their findings to develop a new ... be caused by inflammation or other problems. They reported ... in clinical trials, in ACS, Journal of Medicinal ... decades ago, scientists had pegged a compound called capsaicin ...
(Date:8/20/2014)... gene therapy developed by researchers at the University of ... mice from a life-threatening heart condition caused by muscular ... said Yi Lai, Ph.D., the leading author of the ... of Medicine,s Department of Molecular Microbiology and Immunology. "This ... could lead to a treatment for people with this ...
Breaking Biology News(10 mins):$14.5 million grant awarded to continue anthrax studies 2Gene therapy protects mice from lethal heart condition, MU researchers find 2
... February 5, 2013 What do microbes have to do with ... a microbe and every step in the brewing process helps ... If the Yeast Ain,t Happy, Ain,t Nobody Happy: The Microbiology of ... time someone brews a batch of beer, in a very real ...
... view the causes of obesity may impact the advice ... new study led by researchers at the Johns Hopkins ... between primary care physicians, beliefs about the causes of ... that physicians who believed over consumption of food to ...
... this advance is almost comparable to the leap from ... Cotte and Fatih Toy, have designed a device that ... living biological tissues at the nanoscale. Their research is ... of the Microvision and Microdiagnostics Group in EPFL,s School ...
Cached Biology News:Yeast we can! New report answers questions on microbiology and beer 2Physicians' belief about obesity causes impacts advice and care 2Peering into living cells -- without dye nor fluophore 2